Document:

EX-10.10

 Exhibit 10.10 

TRANSLATE BIO, INC. 
 2018
EMPLOYEE STOCK PURCHASE PLAN 
 The purpose of this 2018 Employee Stock Purchase Plan (this “Plan”) is to provide eligible
employees of Translate Bio, Inc. (the “Company”) and certain of its subsidiaries with opportunities to purchase shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), commencing at such time
and on such dates as the Board of Directors of the Company (the “Board”) shall determine. Subject to adjustment under Section 15 hereof, the number of shares of Common Stock that have been approved for this purpose is the sum of: 

(a) 2,326,076 shares of Common Stock; plus 

(b) an annual increase to be added on the first day of each fiscal year, commencing on January 1, 2019 and ending on
January 1, 2029, equal to the least of (i) 4,652,152 shares of Common Stock, (ii) 1% of the outstanding shares on such date and (iii) an amount determined by the Board. 

This Plan is intended to qualify as an “employee stock purchase plan” as defined in Section 423 of the Internal Revenue Code of 1986, as
amended (the “Code”), and the regulations issued thereunder, and shall be interpreted consistent therewith. 
 1.
Administration. The Plan will be administered by the Board or by a Committee appointed by the Board (the “Committee”). The Board or the Committee has authority to make rules and regulations for the administration of the Plan and its
interpretation and decisions with regard thereto shall be final and conclusive. 
 2. Eligibility. All employees of the Company and
all employees of any subsidiary of the Company (as defined in Section 424(f) of the Code) designated by the Board or the Committee from time to time (a “Designated Subsidiary”), are eligible to participate in any one or more of the
offerings of Options (as defined in Section 9) to purchase Common Stock under the Plan provided that: 
 (a) they are
customarily employed by the Company or a Designated Subsidiary for more than 20 hours a week and for more than five months in a calendar year; 

(b) they have been employed by the Company or a Designated Subsidiary for at least three (3) months prior to enrolling in
the Plan; and 
 (c) they are employees of the Company or a Designated Subsidiary on the first day of the applicable Plan
Period (as defined below). 
 No employee may be granted an Option hereunder if such employee, immediately after the Option is granted,
owns 5% or more of the total combined voting power or value of the stock of the Company or any subsidiary. For purposes of the preceding sentence, the attribution rules of Section 424(d) of the Code shall apply in determining the
stock ownership of an employee, and all stock that the employee has a contractual right to purchase shall be treated as stock owned by the employee. 

 The Company retains the discretion to determine which eligible employees may participate in an
offering pursuant to and consistent with Treasury Regulation Sections 1.423-2(e) and (f). 
 3.
Offerings. The Company will make one or more offerings (“Offerings”) to employees to purchase stock under this Plan. Offerings will begin at such time and on such dates as the Board shall determine, or the first business day
thereafter (such dates, the “Offering Commencement Dates”). Each Offering Commencement Date will begin a six (6) month period (a “Plan Period”) during which payroll deductions will be made and held for the purchase of Common
Stock at the end of the Plan Period. However, the Board or the Committee may, at its discretion, choose a different Plan Period of not more than twelve (12) months for Offerings. 

4. Participation. An employee eligible on the Offering Commencement Date of any Offering may participate in such Offering by completing
and forwarding either a written or electronic payroll deduction authorization form to the employee’s appropriate payroll office at least 15 days prior to the applicable Offering Commencement Date. The form will authorize a regular payroll
deduction from the Compensation received by the employee during the Plan Period. Unless an employee files a new form or withdraws from the Plan, his or her deductions and purchases will continue at the same rate for future Offerings under the Plan
as long as the Plan remains in effect. The term “Compensation” means the amount of money reportable on the employee’s Federal Income Tax Withholding Statement, excluding overtime, shift premium, incentive or bonus awards, allowances
and reimbursements for expenses such as relocation allowances for travel expenses, income or gains associated with the grant or vesting of restricted stock, income or gains on the exercise of Company stock options or stock appreciation rights, and
similar items, whether or not shown or separately identified on the employee’s Federal Income Tax Withholding Statement, but including, in the case of salespersons, sales commissions to the extent determined by the Board or the Committee. 

5. Deductions. The Company will maintain payroll deduction accounts for all participating employees. With respect to any Offering made
under this Plan, an employee may authorize a payroll deduction in any percentage amount (in whole percentages) up to a maximum of 15% of the Compensation he or she receives during the Plan Period
or such shorter period during which deductions from payroll are made. The Board or the Committee may, at its discretion, designate a lower maximum contribution rate. The minimum payroll deduction is such percentage of Compensation as may be
established from time to time by the Board or the Committee. 
 6. Deduction Changes. An employee may decrease or discontinue his or
her payroll deduction once during any Plan Period, by filing either a written or electronic new payroll deduction authorization form. However, an employee may not increase his or her payroll deduction during a Plan Period. If an employee
elects to discontinue his or her payroll deductions during a Plan Period, but does not elect to withdraw his or her funds pursuant to Section 8 hereof, funds deducted prior to his or her election to discontinue will be applied to the purchase
of Common Stock on the Exercise Date (as defined below). 

  
 - 2 - 

 7. Interest. Interest will not be paid on any employee accounts, except to the extent that
the Board or the Committee, in its sole discretion, elects to credit employee accounts with interest at such rate as it may from time to time determine. 

8. Withdrawal of Funds. An employee may at any time prior to the close of business on the fifteenth business day prior to the end of a
Plan Period and for any reason permanently draw out the balance accumulated in the employee’s account and thereby withdraw from participation in an Offering. Partial withdrawals are not permitted. The employee may not begin participation again
during the remainder of the Plan Period during which the employee withdrew his or her balance. The employee may participate in any subsequent Offering in accordance with terms and conditions established by the Board or the Committee. 

9. Purchase of Shares. 

(a) Number of Shares. On the Offering Commencement Date, the Company will grant to each eligible employee who is then a participant in
the Plan an option (an “Option”) to purchase on the last business day of such Plan Period (the “Exercise Date”) at the applicable purchase price (the “Option Price”) up to that number of shares of Common Stock
determined by multiplying $2,083 by the number of full months in the Plan Period and dividing the result by the closing price (as determined below) on the Offering Commencement Date; provided, however, that no employee may be granted an Option which
permits his or her rights to purchase Common Stock under this Plan and any other employee stock purchase plan (as defined in Section 423(b) of the Code) of the Company and its subsidiaries, to accrue at a rate which exceeds $25,000 of the fair
market value of such Common Stock (determined at the date such Option is granted) for each calendar year in which the Option is outstanding at any time; and, provided, further, however, that the Committee may, in its discretion, set a fixed maximum
number of shares of Common Stock that each eligible employee may purchase per Plan Period which number may not be greater than the number of shares of Common Stock determined by using the formula in the first clause of this Section 9(a) and
which number shall be subject to the second clause of this Section 9(a). 
 (b) Option Price. The Board or the Committee shall
determine the Option Price for each Plan Period, including whether such Option Price shall be determined based on the lesser of the closing price of the Common Stock on (i) the first business day of the Plan Period or (ii) the Exercise
Date, or shall be based solely on the closing price of the Common Stock on the Exercise Date; provided, however, that such Option Price shall be at least 85% of the applicable closing price. In the absence of a determination by the Board or the
Committee, the Option Price will be 85% of the lesser of the closing price of the Common Stock on (i) the first business day of the Plan Period or (ii) the Exercise Date. The closing price shall be (a) the closing price (for the
primary trading session) on any national securities exchange on which the Common Stock is listed or (b) the average of the closing bid and asked prices in the
over-the-counter-market, whichever is applicable, as published in The Wall Street Journal or another source selected by the Board or the Committee. If no sales of
Common Stock were made on such a day, the price of the Common Stock shall be the reported price for the next preceding day on which sales were made. 

  
 - 3 - 

 (c) Exercise of Option. Each employee who continues to be a participant in the Plan on the
Exercise Date shall be deemed to have exercised his or her Option at the Option Price on such date and shall be deemed to have purchased from the Company the number of whole shares of Common Stock reserved for the purpose of the Plan that his or her
accumulated payroll deductions on such date will pay for, but not in excess of the maximum numbers determined in the manner set forth above. 

(d) Return of Unused Payroll Deductions. Any balance remaining in an employee’s payroll deduction account at the end of a Plan
Period will be automatically refunded to the employee, except that any balance that is less than the purchase price of one share of Common Stock will be carried forward into the employee’s payroll deduction account for the following Offering,
unless the employee elects not to participate in the following Offering under the Plan, in which case the balance in the employee’s account shall be refunded. 

10. Issuance of Certificates. Certificates representing shares of Common Stock purchased under the Plan may be issued only in the name
of the employee, in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or (in the Company’s sole discretion) in the name of a brokerage firm, bank, or other nominee holder designated by the
employee. The Company may, in its sole discretion and in compliance with applicable laws, authorize the use of book entry registration of shares in lieu of issuing stock certificates. 

11. Rights on Retirement, Death or Termination of Employment. If a participating employee’s employment ends before the last
business day of a Plan Period, no payroll deduction shall be taken from any pay then due and owing to the employee and the balance in the employee’s account shall be paid to the employee. In the event of the employee’s death before the
last business day of a Plan Period, the Company shall, upon notification of such death, pay the balance of the employee’s account (a) to the executor or administrator of the employee’s estate or (b) if no such executor or
administrator has been appointed to the knowledge of the Company, to such other person(s) as the Company may, in its discretion, designate. If, before the last business day of the Plan Period, the Designated Subsidiary by which an employee is
employed ceases to be a subsidiary of the Company, or if the employee is transferred to a subsidiary of the Company that is not a Designated Subsidiary, the employee shall be deemed to have terminated employment for the purposes of this
Plan. 
 12. Optionees Not Stockholders. Neither the granting of an Option to an employee nor the deductions from his or her pay
shall make such employee a stockholder of the shares of Common Stock covered by an Option under this Plan until he or she has purchased and received such shares. 

13. Options Not Transferable. Options under this Plan are not transferable by a participating employee other than by will or the laws of
descent and distribution, and are exercisable during the employee’s lifetime only by the employee. 
 14. Application of Funds.
All funds received or held by the Company under this Plan may be combined with other corporate funds and may be used for any corporate purpose. 

  
 - 4 - 

 15. Adjustment for Changes in Common Stock and Certain Other Events.  

(a) Changes in Capitalization. In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of
shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash dividend, (i) the
number and class of securities available under this Plan, (ii) the share limitations set forth in Section 9, and (iii) the Option Price shall be equitably adjusted to the extent determined by the Board or the Committee. 

(b) Reorganization Events. 

(1) Definition. A “Reorganization Event” shall mean: (a) any merger or consolidation of the Company with or into another
entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (b) any transfer or disposition of all of the Common Stock of the
Company for cash, securities or other property pursuant to a share exchange or other transaction or (c) any liquidation or dissolution of the Company. 

(2) Consequences of a Reorganization Event on Options. In connection with a Reorganization Event, the Board or the Committee may take
any one or more of the following actions as to outstanding Options on such terms as the Board or the Committee determines: (i) provide that Options shall be assumed, or substantially equivalent Options shall be substituted, by the acquiring or
succeeding corporation (or an affiliate thereof), (ii) upon written notice to employees, provide that all outstanding Options will be terminated immediately prior to the consummation of such Reorganization Event and that all such outstanding
Options will become exercisable to the extent of accumulated payroll deductions as of a date specified by the Board or the Committee in such notice, which date shall not be less than ten (10) days preceding the effective date of the
Reorganization Event, (iii) upon written notice to employees, provide that all outstanding Options will be cancelled as of a date prior to the effective date of the Reorganization Event and that all accumulated payroll deductions will be
returned to participating employees on such date, (iv) in the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each share surrendered in the
Reorganization Event (the “Acquisition Price”), change the last day of the Plan Period to be the date of the consummation of the Reorganization Event and make or provide for a cash payment to each employee equal to (A) (1) the
Acquisition Price times (2) the number of shares of Common Stock that the employee’s accumulated payroll deductions as of immediately prior to the Reorganization Event could purchase at the Option Price, where the Acquisition Price is
treated as the fair market value of the Common Stock on the last day of the applicable Plan Period for purposes of determining the Option Price under Section 9(b) hereof, and where the number of shares that could be purchased is subject to the
limitations set forth in Section 9(a), minus (B) the result of multiplying such number of shares by such Option Price, (v) provide that, in connection with a liquidation or dissolution of the Company, Options shall convert into the
right to receive liquidation proceeds (net of the Option Price thereof) and (vi) any combination of the foregoing. 
 For purposes of
clause (i) above, an Option shall be considered assumed if, following consummation of the Reorganization Event, the Option confers the right to purchase, 

  
 - 5 - 

 
for each share of Common Stock subject to the Option immediately prior to the consummation of the Reorganization Event, the consideration (whether cash, securities or other property) received as
a result of the Reorganization Event by holders of Common Stock for each share of Common Stock held immediately prior to the consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration
chosen by the holders of a majority of the outstanding shares of Common Stock); provided, however, that if the consideration received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or
an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the consideration to be received upon the exercise of Options to consist solely of such number of shares of common stock of the
acquiring or succeeding corporation (or an affiliate thereof) that the Board determines to be equivalent in value (as of the date of such determination or another date specified by the Board) to the per share consideration received by holders of
outstanding shares of Common Stock as a result of the Reorganization Event. 
 16. Amendment of the Plan. The Board may at any time,
and from time to time, amend or suspend this Plan or any portion thereof, except that (a) if the approval of any such amendment by the shareholders of the Company is required by Section 423 of the Code, such amendment shall not be effected
without such approval, and (b) in no event may any amendment be made that would cause the Plan to fail to comply with Section 423 of the Code. 

17. Insufficient Shares. If the total number of shares of Common Stock specified in elections to be purchased under any Offering plus
the number of shares purchased under previous Offerings under this Plan exceeds the maximum number of shares issuable under this Plan, the Board or the Committee will allot the shares then available on a
pro-rata basis. 
 18. Termination of the Plan. This Plan may be terminated at any time by the
Board. Upon termination of this Plan all amounts in the accounts of participating employees shall be promptly refunded. 
 19.
Governmental Regulations. The Company’s obligation to sell and deliver Common Stock under this Plan is subject to listing on a national stock exchange (to the extent the Common Stock is then so listed or quoted) and the approval of
all governmental authorities required in connection with the authorization, issuance or sale of such stock. 
 20. Governing Law. The
Plan shall be governed by Delaware law except to the extent that such law is preempted by federal law. 
 21. Issuance of Shares.
Shares may be issued upon exercise of an Option from authorized but unissued Common Stock, from shares held in the treasury of the Company, or from any other proper source. 

22. Notification upon Sale of Shares. Each employee agrees, by participating in the Plan, to promptly give the Company notice of any
disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased. 

  
 - 6 - 

 23. Grants to Employees in Foreign Jurisdictions. The Company may, to comply with the laws
of a foreign jurisdiction, grant Options to employees of the Company or a Designated Subsidiary who are citizens or residents of such foreign jurisdiction (without regard to whether they are also citizens of the United States or resident aliens
(within the meaning of Section 7701(b)(1)(A) of the Code)) with terms that are less favorable (but not more favorable) than the terms of Options granted under the Plan to employees of the Company or a Designated Subsidiary who are resident in
the United States. Notwithstanding the preceding provisions of this Plan, employees of the Company or a Designated Subsidiary who are citizens or residents of a foreign jurisdiction (without regard to whether they are also citizens of the United
States or resident aliens (within the meaning of Section 7701(b)(1)(A) of the Code)) may be excluded from eligibility under the Plan if (a) the grant of an Option under the Plan to a citizen or resident of the foreign jurisdiction is
prohibited under the laws of such jurisdiction or (b) compliance with the laws of the foreign jurisdiction would cause the Plan to violate the requirements of Section 423 of the Code. The Company may add one or more appendices to this Plan
describing the operation of the Plan in those foreign jurisdictions in which employees are excluded from participation or granted less favorable Options. 

24. Authorization of Sub-Plans. The Board may from time to time establish one or more sub-plans under the Plan with respect to one or more Designated Subsidiaries, provided that such sub-plan complies with Section 423 of the Code. 

25. Withholding. If applicable tax laws impose a tax withholding obligation, each affected employee shall, no later than the date of the
event creating the tax liability, make provision satisfactory to the Board for payment of any taxes required by law to be withheld in connection with any transaction related to Options granted to or shares acquired by such employee pursuant to the
Plan. The Company may, to the extent permitted by law, deduct any such taxes from any payment of any kind otherwise due to an employee. 

26. Effective Date and Approval of Shareholders. The Plan shall take effect as of the immediately prior to the effectiveness of the
Company’s registration statement with respect to its initial public offering, subject to approval by the shareholders of the Company as required by Section 423 of the Code, which approval must occur within twelve months of the adoption of
the Plan by the Board. 
  

	
	Adopted by the Board of Directors on
	March 7, 2018
	
	Approved by the stockholders on
	[                            ]

  
 - 7 -EX-10.11

 Exhibit 10.11 

October 31, 2014 
 BY EMAIL 

Mr. Ronald Renaud 

Re:    Employment Agreement 
 Dear
Ron: 
 On behalf of RaNA Therapeutics, LLC (“RaNA” or the “Company”), I am pleased to offer you the position of the
Company’s Chief Executive Officer (“CEO”). The terms of your employment are set forth below. 

1.    Position. As the Company’s CEO you will report to the Board of Directors of the Company (the “Board”).
This is a full-time employment position and you will have the usual and customary duties and responsibilities associated with the position of Chief Executive Officer. It is understood and agreed that, while you are employed by the Company, you will
not engage in any other employment, consulting or other business activities (whether full-time or part-time), without the prior written consent of the Board, provided, however, that you may engage in religious, charitable and other community
activities so long as such activities do not interfere or conflict with your obligations to the Company. Commencing on the Start Date (as defined below) and continuing during your employment, you will be elected to and serve on the Board. Upon the
ending of your employment as CEO, you shall immediately resign from the Board as well as from any other position(s) to which you were elected or appointed in connection with your position as CEO. 

2.    Start Date. Your employment with the Company will begin on or before November 17, 2014. For purposes of this Agreement,
the actual first day of your employment with the Company shall be referred to as the “Start Date.” 

3.    Salary. During the first year of your employment, the Company will pay you a base salary at the rate of $375,000 per year,
payable in accordance with the Company’s standard payroll schedule and subject to applicable deductions and withholdings (the “Base Salary”). Thereafter, the Base Salary will be subject to periodic review and upward adjustments
at the Board’s discretion. You will be reimbursed by the Company for expenses incurred in connection with the performance of your duties as CEO subject to compliance with applicable Company policies pertaining thereto, such as providing
receipts for such expenses. 
 4.    Bonus Compensation. You will be eligible to receive annual performance bonuses, targeted at
fifty (50%) percent of your then Base Salary (the “Target Bonus”). The actual bonus is discretionary and will be subject to assessment of your performance, as well as business conditions at the Company as determined by the Board or
its compensation committee. Except as provided in section 8 below, you must be employed on the date a bonus is paid to earn any part of a bonus. Your bonus in 2014, if any, will be pro-rated for partial year
service. 

 Ronald Renaud 

October 31, 2014 
  Page
 2
 
  

 5.    Equity 

(a)    Subject to final approval by the Board and receipt of all other required approvals to be secured contemporaneously, through a Board
of Director action, with the signing and approval of this Agreement, effective on the Start Date, you will be awarded 3,040,819 Incentive Units, which equals 7% of the Company’s currently outstanding equity on a fully-diluted basis as of the
date hereof, including for such purposes the conversion of all convertible securities (the “Equity Award”). The Equity Award shall be subject to the terms and conditions set forth in the Amended and Restated Operating Agreement of
the Company, dated October 4, 2013, as amended and supplemented from time to time (the “Operating Agreement”), and the Company’s standard form agreement for the award of Incentive Units (the “Grant
Agreement”). The Incentive Units will be issued with a Strike Price1 determined in accordance with the Operating Agreement. For informational purposes, on May 1, 2014, the Board most
recently determined that the then-current Strike Price was $37,149,026. The Equity Award shall be subject to a four-year vesting schedule in which 25% of the Incentive Units subject to the Equity Award shall vest on the one-year anniversary of the Start Date and the remainder shall vest ratably on a monthly basis over the following 36 months, subject to continued employment. Notwithstanding the above, in the event that the Company
terminates your employment without Cause or you resign with Good Reason (both as defined below), within 12 months following a Sale of the Company (as defined below), you shall immediately vest in all Incentive Units subject to the Equity Award. 

(b)    The Board may also, in its discretion, award you additional Incentive Units subject to time based and/or performance based vesting.
The terms of the Operating Agreement and any associated award agreement (collectively the “Equity Documents”) shall apply to any equity grant. In the event of any conflict between the terms set forth in this Agreement and the terms
of the Equity Documents, the terms of the Equity Documents shall control. 
 6.    Benefits/Vacation. You will be eligible to
participate in the employee benefits and insurance programs generally made available to the Company’s full-time employees, including with respect to health insurance. You will be entitled to four (4) weeks of paid vacation per year,
accrued on a pro-rata basis. 
 7.    At-Will
Employment; Accrued Obligations. Your employment is “at will,” meaning you or the Company may terminate it at any time for any or no reason. Except as provided in section 8 below, in the event of the ending of your employment for any
reason, the Company shall pay you: (i) your base salary plus any accrued but unused vacation through your last day of employment (the “Date of Termination”), and (ii) the amount of any documented expenses properly incurred
by you on behalf of the Company prior to any such termination and not yet reimbursed (the “Accrued Obligations”). 
  

 

	1 	“Strike Price” is defined in the Operating Agreement as the Board-determined current aggregate fair market value (“FMV”) of the Company, so that upon a hypothetical liquidation of the Company on the
date of issuance of such Incentive Units in which Company sold its assets for their FMV, satisfied its liabilities and distributed the net proceeds to the holders of Common Units and Preferred Units in liquidation of the Company, the recipient of
such Incentive Units would not be entitled to receive any distributions on liquidation. By that mechanism, the holder of an Incentive Unit participates in the distribution of the incremental increase in value of the Company that accrues after the
Incentive Unit is granted. 

 Ronald Renaud 

October 31, 2014 
  Page
 3
 
  

 8.    Termination Benefits. In the event that the Company terminates your
employment without Cause or you resign for Good Reason, both as defined below, and provided you enter into, do not revoke and comply with the terms of a separation agreement substantially in the form attached hereto as Exhibit A (the
“Release”), the Company will provide you with the following “Termination Benefits”: 

(a)    if elected, continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C.
§ 1161 et seq. (commonly known as “COBRA”), with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and you as in effect on the Date of Termination until the earlier of:
(i) twelve (12) months from the Date of Termination or (ii) the date you and your dependents become eligible for health benefits through another employer or otherwise become ineligible for COBRA; and 

(b)    either (i) continuation of your Base Salary and a pro-rata portion of
your Target Bonus (based on the number of months in the applicable severance period and presuming 100% achievement of corporate and personal objectives) for twelve (12) months following the Date of Termination, or (ii) in the event that
the Company terminates your employment without Cause or you resign for Good Reason, both as defined below, within twelve (12) months following a Sale of the Company (as defined below), continuation of your Base Salary and an amount equal to the
greater of (A) your Target Bonus for the fiscal year during which the Date of Termination occurred (presuming 100% achievement of corporate and personal objectives) and (B) the actual bonus you were paid in respect of the most recent
fiscal year ending prior to the Date of Termination (such amounts are the “Salary Continuation Payments” and the “Bonus Continuation Payments”). In the event that the Company terminates your employment without Cause
or you resign for Good Reason, both as defined below, within twelve (12) months following a Sale of the Company (as defined below), the Salary Continuation Payments and Bonus Continuation Payments shall be payable for a period of eighteen
(18) months if the Date of Termination occurs prior to the second anniversary of the Start Date and shall otherwise continue for a period of twenty-four (24) months. 

The Salary Continuation Payments shall commence within 35 days after the Date of Termination and shall be payable in substantially equal installments in
accordance with the Company’s regular payroll practice over the applicable severance period, provided the Release has become fully effective. The Bonus Continuation payments, if any, shall be payable on the dates for payment of bonuses for the
respective periods to the remaining executive employees of the Company. In the event you miss a regular payroll period between the Date of Termination and first Salary Continuation Payment date, the first Salary Continuation Payment shall include a
“catch up” payment. Solely for purposes of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), each Salary and Bonus Continuation Payment is considered a separate payment. For the avoidance of
doubt, in the event your employment is terminated for any reason other than a termination by the Company without Cause or your resignation for Good Reason you will be entitled to the Accrued Obligations but you will not be entitled to any of the
Termination Benefits. 

 Ronald Renaud 

October 31, 2014 
  Page
 4
 
  

 For purposes of this Agreement, 

“Cause” means any of the following: (i) dishonesty, embezzlement, misappropriation of assets or property of the Company; (ii) gross
negligence, willful misconduct, theft, fraud or breach of fiduciary duty to the Company; (iii) violation of federal or state securities laws; (iv) your material breach of this Offer Letter, the Restrictive Covenant Agreement or any other
written agreement between you and the Company; (v) the conviction of a felony, or any crime involving moral turpitude, including a plea of guilty or no lo contendre; or (vi) continued
non-performance of your responsibilities hereunder provided the Board has provided you with notice of such nonperformance and you have been provided with a reasonable opportunity to cure not to exceed thirty
(30) days. 
 “Sale of the Company” means the consummation of a Capital Transaction (as defined in the Operating Agreement) of RaNA
LLC that results in the distribution of Capital Transaction Proceeds (as defined in the Operating Agreement) to the Members (as defined in the Operating Agreement) in accordance with the Operating Agreement. 

“Good Reason” means that you have complied with the “Good Reason Process” (hereinafter defined) following the occurrence of
any of the following actions undertaken by the Company without your express prior written consent: (i) failure of the Company to authorize and approve the Equity Award as and when described in Section 5(a) above, (ii) the material
diminution in your responsibilities, authority and function; (iii) a material reduction in your base salary, provided, however, that Good Reason shall not be deemed to have occurred in the event of a reduction in your base salary that is
pursuant to a salary reduction program affecting substantially all of the senior level employees of the Company and that does not adversely affect you to a greater extent than other similarly situated employees; (iv) a material breach of this
Offer Letter or any other written agreement between you and the Company; or (v) a change in the geographic location at which you must regularly report to work and perform services to a location that is more than fifty (50) miles from
Cambridge, Massachusetts, except for required travel on the Company’s business. “Good Reason Process” means that (i) you have reasonably determined in good faith that a “Good Reason” condition has occurred;
(ii) you have notified the Company in writing of the first occurrence of the Good Reason condition within sixty (60) days of the first occurrence of such condition; (iii) you have cooperated in good faith with the Company’s
efforts, for a period not less than thirty (30) days following such notice (the “Cure Period”), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) you
terminate your employment within sixty (60) days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred. 

9.    Confidential Information and Restricted Activities. By signing this Agreement, you represent that you have
carefully read and considered all the terms and conditions of this Agreement, including the restraints imposed on you pursuant to the Company’s Non­Competition, Non-Solicitation, Confidentiality and Assignment Agreement (the
“Restrictive Covenant Agreement”) attached as Exhibit B, the terms of which are incorporated by reference herein. You agree without reservation that these restraints are necessary for the reasonable and proper protection of the
Company and its affiliates, and that each and every one of the restraints is reasonable in respect to subject matter, length of time and geographic area. 

 Ronald Renaud 

October 31, 2014 
  Page
 5
 
  

 You further agree that, if were you to breach any of the covenants contained in this Agreement or the
Restrictive Covenant Agreement, in addition to the Company’s other legal and equitable remedies, the Company may suspend or cease any Termination Benefits to which you might otherwise be entitled. Any such suspension or termination of the
Termination Benefits by the Company in the event of a breach by you shall not affect your ongoing obligations to the Company. 

10.    Taxes; Section 409A 

(a)    All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes
and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its board
of directors related to tax liabilities arising from your compensation. 
 (b)    Anything in this Agreement to the contrary
notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Code, the Company determines that you are a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the
Code, then to the extent any payment or benefit that you becomes entitled to under this Agreement on account of your separation from service would be considered deferred compensation subject to the 20% additional tax imposed pursuant to
Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one
day after your separation from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering
amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original
schedule. All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All
reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement
in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. To the extent that any payment or benefit described in this Agreement
constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon your termination of employment, then such
payments or benefits shall be payable only upon your “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation
Section l.409A-1(h). The Company and you intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to
its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. The Company makes no representation or warranty and shall have no liability to
you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. 

 Ronald Renaud 

October 31, 2014 
  Page
 6
 
  

 (c)    Interpretation, Amendment and Enforcement. This Agreement, including the
Restrictive Covenant Agreement and the Equity Documents, constitutes the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or
understandings (whether written, oral or implied) between you and the Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in
any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the “Disputes”) will be governed by Massachusetts law, excluding laws relating to conflicts or choice of
law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the Commonwealth of Massachusetts in connection with any Dispute or any claim related to any Dispute. 

11.    Assignment. Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law
or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenant Agreement) without your consent to any
affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets. This Agreement shall inure to the
benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns. 

12.    Miscellaneous. This Agreement may not be modified or amended, and no breach shall be deemed to be waived, unless agreed to
in writing by you and a Board member of the Company. The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content of any provision of this Agreement. The words “include,”
“includes” and “including” when used herein shall be deemed in each case to be followed by the words “without limitation.” This Agreement may be executed in two or more counterparts, each of which shall be
an original and all of which together shall constitute one and the same instrument. 
 13.    Other Terms. This offer is
contingent on the completion of successful background checks, as determined by the Company. By signing this Agreement, you represent to the Company that you have no contractual commitments or other legal obligations that would or may prohibit you
from performing your duties for the Company. As with any employee, you must submit satisfactory proof of your identity and your legal authorization to work in the United States. 

 Ronald Renaud 

October 31, 2014 
  Page
 7
 
  

 Please acknowledge, by signing below, that you have accepted this Agreement. 

 

			
	Very truly yours,
	RANA THERAPEUTICS, LLC
		
	By:	 	 /s/ Daniel Lynch

	Name:	 	Daniel Lynch
	Title:	 	Chairman
	Hereunto Duly Authorized

 I have read and accept this employment offer: 
  

	
	 /s/ Ronald Renaud

	Ronald Renaud
	Dated: October 31, 2014

 Exhibit A 

Form of Release 
 (copy
attached hereto) 

 GENERAL RELEASE AGREEMENT 

WHEREAS, RaNA Therapeutics, LLC (“RaNA” or the “Company”), and Ronald Renaud (the “Executive,”
together with the Company, the “Parties”), entered into an employment agreement dated October 31, 2014 (the “Employment Agreement”); 

WHEREAS, among other things, the Employment Agreement states that the Company may terminate Executive’s employment at any time; 

WHEREAS, the Company has elected to terminate Executive’s employment, effective [DATE] (the “Date of Termination”); 

WHEREAS, the Employment Agreement provides that, in the event that the Company terminates Executive’s employment without Cause or the
Executive resigns for Good Reason, both as defined in the Employment Agreement, and provided the Executive enters into, does not revoke and complies with the terms of a separation agreement substantially in the form attached hereto as Exhibit A to
the Employment Agreement (the “Release”), the Company will provide Executive with the certain Termination Benefits as defined in the Employment Agreement; 

WHEREAS, this General Release Agreement (the “Release”) is the separation agreement referenced in the Employment Agreement. 

NOW THEREFORE, the Parties hereby agree as follows: 
  

	1.	Termination Benefits. As consideration for the Executive entering into and complying with this Release, the Executive shall be entitled to the Termination Benefits as defined in and on the terms and conditions
set forth in the Employment Agreement. The Executive is entitled to no other post-employment payments or benefits. 

  

	2.	Release of Claims. The Executive, for himself and his heirs, assigns, executors and administrators in all of his capacities, including, but not limited to, his capacity as an individual, shareholder, trustee or
otherwise, voluntarily releases and forever discharges the Company, all of its affiliates and related entities and each of its and their predecessors, successors, assigns, and current and former members, partners, directors, officers, employees,
stockholders, representatives, attorneys, agents, and all persons acting by, though, under or in concert with any of the foregoing (any and all of whom or which are hereinafter referred to as the “Releasees”), from any and all
charges, complaints, claims, liabilities, obligations, promises, agreements, controversies, damages, actions, causes of action, suits, rights, demands, costs, losses, debts and expenses (including attorney’s fees and costs actually incurred),
of any nature whatsoever, known or unknown (collectively, “Claims”) that as of the date when Executive signs this Release, the Executive now has, owns or holds, or claims to have, own, or hold, or that he at any time had, owned, or held,
or claimed to have had, owned, or held against any Releasee. This general release of Claims includes, without implication of limitation, the complete release of all Claims: 

 

	 	•	 	relating to the Executive’s employment by the Company and the termination of his employment relationship; 

  
 1 

	 	•	 	of wrongful discharge; 

  

	 	•	 	of breach of contract; 

  

	 	•	 	of retaliation or discrimination of any kind including, without limitation, under federal, state or local law (including, without limitation, Claims of age discrimination or retaliation under the Age Discrimination in
Employment Act, Claims of disability discrimination or retaliation under the Americans with Disabilities Act, Claims of discrimination or retaliation under Title VII of the Civil Rights Act of 1964, Massachusetts General Laws Chapter 151B, and any
Claims of discrimination or retaliation under state law); 

  

	 	•	 	any and all Claims in the nature of so-called whistleblower complaints to the extent permitted by applicable law; 

 

	 	•	 	under any other federal or state statute, to the fullest extent that Claims may be released; 

  

	 	•	 	of defamation, deceit, misrepresentation, or other torts; 

  

	 	•	 	of violation of public policy; 

  

	 	•	 	for salary, bonuses, vacation pay, stock, stock options, or any other compensation or benefits, including without limitation pursuant to the Massachusetts Wage Act; and 

 

	 	•	 	for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney’s fees. 

provided, however, that this release shall not affect your rights under this Release. 

Executive agrees not to accept damages of any nature, other equitable or legal remedies for Executive’s own benefit or attorney’s
fees or costs from any of the Releasees with respect to any Claim released by this Release. 
  

	3.	Return of Property. Executive represents that he has returned to the Company all Company property, including, without limitation, computer equipment, software, keys and access cards, credit cards, files and any
documents (including computerized data and any copies made of any computerized data or software) containing information concerning the Company, its business or its business relationships. After returning all Company property, Executive shall, upon
written instruction from the Company, delete and finally purge any duplicates of files or documents that may contain Company or customer information from any non-Company computer or other device that remains
Executive’s property after the Termination Date. 

  

	4.	Nondisparagement. Executive agrees not to make any disparaging statements, whether written or oral, concerning the Company or any of its affiliates or current or former officers, directors, shareholders,
employees or agents. 

  

	5.	Statutory Benefit Rights. Nothing in this Release is intended to release or waive the Executive’s rights pursuant to COBRA or apply for unemployment insurance benefits. 

 

	6.	Non-Admission. Nothing in this Release shall be construed as an admission by the Company. 

  
 2 

	7.	Existing Obligations. The Executive reaffirms his ongoing obligations under the Employee, Non-Competition, Non-Solicitation,
Confidentiality and Assignment Agreement dated [DATE] (the “Restrictive Covenant Agreement”) which was a condition of Executive’s employment, the terms of which are incorporated by reference into this Release. 

 

	8.	No Assignment. The Executive represents that he has not assigned to any other person or entity any Claims against any Releasee. 

 

	9.	Right to Consider and Revoke Release. The Executive acknowledges that he has been given the opportunity to consider this Release for twenty-one (21) days from the day
he receives it (the “Consideration Period”) and any changes to this Release shall not extend or otherwise affect the original Consideration Period. If the Executive signs this Release within less than
twenty-one (21) days, he acknowledges that such decision was entirely voluntary and that he had the opportunity to consider this Release until the end of the Consideration Period. To accept this Release,
the Executive shall deliver a signed Release to              within the Consideration Period. For a period of seven (7) days from the date when the Executive executes this Release (the
“Revocation Period”), he shall retain the right to revoke this Release by written notice that is received by              on or before the last day of the Revocation Period. This
Release shall take effect only if it is executed within the Consideration Period as set forth above and if it is not revoked pursuant to the preceding sentence. If those conditions are satisfied, this Release shall become effective and enforceable
on the date immediately following the last day of the Revocation Period (“Effective Release Date”). 

  

	10.	Termination or Suspension of Payments. Executive acknowledges that his right to the Termination Benefits is conditional on his compliance with the terms of this Release, including the terms that are incorporated
by reference. Consistent with this, if the Executive fails to comply with any of the terms of this Release, in addition to any other legal or equitable remedies it may have for such breach, the Company shall have the right to terminate or suspend
the Termination Benefits. The termination or suspension of those payments in the event of such breach by the Executive shall not affect the ongoing applicability of the terms of this Release. 

 

	11.	Tax Treatment. The Company shall undertake to make deductions, withholdings and tax reports with respect to payments and benefits under this Release to the extent that it reasonably and in good faith determines
that it is required to make such deductions, withholdings and tax reports. Payments under this Release shall be in amounts net of any such deductions or withholdings. Nothing in this Release shall be construed to require the Company to make any
payments to compensate Executive for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit. 

 

	12.	Other Terms. 

 (a)    Legal Representation; Review of Release.
The Executive acknowledges that he has been advised to discuss all aspects of this Release with his attorney, that he has carefully read and fully understands all of the provisions of this Release and that he is voluntarily entering into this
Release. 

  
 3 

 (b)    Binding Nature of Release. This Release shall be binding upon
the Executive and upon his heirs, administrators, representatives and executors. 
 (c)    Modification of Release;
Waiver. This Release may be amended, only upon a written agreement executed by the Executive and a duly authorized officer of the Company. 

(d)    Severability. If at any future time it is determined by an arbitrator or court of competent jurisdiction
that any covenant, clause, provision or term of this Release is illegal, invalid or unenforceable, the remaining provisions and terms of this Release shall not be affected thereby and the illegal, invalid or unenforceable term or provision shall be
severed from the remainder of this Release. In the event of such severance, the remaining covenants shall be binding and enforceable. 

(e)    Governing Law and Interpretation; Jurisdiction. This Release shall be deemed to be made and entered into in
the Commonwealth of Massachusetts and shall in all respects be interpreted, enforced and governed under the laws of Massachusetts, without giving effect to the conflict of laws provisions of Massachusetts law. The language of all parts of this
Release shall in all cases be construed as a whole, according to its fair meaning, and not strictly for or against either of the Parties. The Executive and the Company hereby agree that the Massachusetts courts shall have the exclusive jurisdiction
to consider any matters related to this Release, including without limitation any claim for violation of this Release. With respect to any such court action, Executive and the Company (i) submit to the jurisdiction of such courts,
(ii) consent to service of process, and (iii) waive any other requirement (whether imposed by statute, rule of court or otherwise) with respect to personal jurisdiction or venue. 

(f)    Entire Agreement. This Agreement (including the Restrictive Covenant Agreement) constitutes the entire
agreement regarding Executive’s employment with the Company and supersedes any previous agreements and understandings between the parties, except [name preserved agreements] shall remain in full force and effect. 

(g)    Absence of Reliance. The Executive acknowledges that he is not relying on any promises or representations by
the Company or its agents, representatives or attorneys of either of them regarding any subject matter addressed in this Release. 

(h)    Assignment; Successors and Assigns, etc. Neither the Company nor the Executive may make any assignment of
this Release or any interest herein, by operation of law or otherwise, without the prior written consent of the other party; provided that the Company may assign its rights under this Release without the consent of the Executive in the event that
the Company shall effect a reorganization, consolidate with or merge into any other corporation, partnership, organization or other entity, or transfer all or substantially all of its properties or assets to any other corporation, partnership,
organization or other entity. This Agreement shall inure to the benefit of and be binding upon the Company and the Executive, their respective successors, executors, administrators, heirs and permitted assigns. 

  
 4 

 (i)    Counterparts. This Agreement may be executed in any number of
counterparts, including by facsimile or PDF, each of which when so executed and delivered shall be taken to be an original, but all of which together shall constitute one and the same document. 

  
 5 

 Exhibit B 

Employee Non-Competition, Non-Solicitation, Confidentiality
and Assignment Agreement 
 (copy attached hereto) 

 RANA THERAPEUTICS, LLC 

Employee Non-Competition, Non-Solicitation, Confidentiality
and Assignment Agreement 
 I, the undersigned, enter into this Agreement with RaNA Therapeutics, LLC (“the Company”). I
acknowledge as a condition of my employment with the Company, and in consideration of my initial and continued employment, I am entering into this Agreement with the Company. For purposes of this Agreement, “Affiliate(s)” means any legal
entity that is directly or indirectly controlled by, or controls or is under common control with, another legal entity, provided that “control” shall mean ownership as to more than 50% of another legal entity or the power to direct
decisions of another legal entity, including, without limitation, the power to direct management and policies of another legal entity, whether by reason of ownership, by contract or otherwise. 

 

 2.    Proprietary Information. I agree that all information, whether or not in
writing, concerning the Company’s business, technology, assets, business relationships or affairs that the Company or any of its Affiliates has not released to the general public (collectively, “Proprietary Information”) is and will
be the exclusive property of the Company and/or such Affiliate(s). By way of illustration, Proprietary Information may include information or material that has not been made generally available to the public, such as: (a) corporate
information, including plans, strategies, methods, policies, resolutions, negotiations or litigation; (b) marketing information, including strategies, methods, customer identities or other information about customers,
prospect identities or other information about prospects, or market analyses or projections; (c) financial information, including cost and performance data, debt arrangements, equity structure; investors and holdings, purchasing
and sales data and price lists; and (d) operational and technological information, including plans, specifications, manuals, forms, templates, software, designs, methods, procedures, formulas, discoveries, inventions,
improvements, concepts and ideas; and (e) personnel information, including personnel lists, reporting or organizational structure, resumes, personnel

 
data, compensation structure, performance evaluations and termination arrangements or documents. Proprietary Information also includes information received in confidence by the Company or any of
its Affiliates from its or their customers or suppliers or other third parties. 
 3.    Recognition of Company’s
Rights. I will not, at any time, without the Company’s prior written permission, either during or after my employment, disclose any Proprietary Information to anyone outside of the Company or, to the extent applicable and necessary, any
of its Affiliates, or use or permit to be used any Proprietary Information for any purpose other than the performance of my duties as an employee of the Company. I will cooperate with the Company and use my best efforts to prevent the unauthorized
disclosure of all Proprietary Information. I will deliver to the Company all copies of Proprietary Information in my possession or control upon the earlier of a request by the Company or termination of my employment. 

4.    Rights of Others. I understand that the Company or any of its Affiliates is now and may hereafter be subject to non-disclosure or confidentiality agreements with third persons that require the Company or any of its Affiliates to protect or refrain

 

  
 1 

 
from use of proprietary information. I agree to be bound by the terms of such agreements in the event I have access to such proprietary information. 

5.    Commitment to the Company; Avoidance of Conflict of Interest. While an employee of the Company, I will devote my full
working time and efforts to the Company’s business and I will not engage in any other business activity that conflicts with my duties to the Company. I will advise the Chairman of the Board of the Company or his or her nominee at such time as
any activity of either the Company or another business presents me with a conflict of interest or the appearance of a conflict of interest as an employee of the Company. I will take whatever action is requested of me by the Company to resolve any
conflict or appearance of conflict that it finds to exist. 
 6.    Developments. I will make full and prompt disclosure
to the Company of all inventions, discoveries, designs, developments, methods, modifications, improvements, processes, algorithms, databases, computer programs, formulae, techniques, trade secrets, graphics or images, audio or visual works, and
other works of authorship (collectively “Developments”), whether or not patentable or copyrightable, that are created, made, conceived or reduced to practice by me (alone or jointly with others) or under my direction during the period of
my employment. I acknowledge that all work performed by me is on a “work for hire” basis, and I hereby do assign and transfer and, to the extent any such assignment cannot be made at present, will assign and transfer, to the Company and
its successors and assigns all my right, (x) title and interest in all Developments that (a) relate to the business of the Company or any of its Affiliates or any customer of or supplier to the Company or any of its Affiliates or any

 
of the products or services being researched, developed, manufactured or sold by the Company or any of its Affiliates or which may be used with such products or services; or (b) result from
tasks assigned to me by the Company; or (c) result from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the Company or any of its Affiliates (“Company-Related
Developments”), and (y) all related patents, patent applications, trademarks and trademark applications, copyrights and copyright applications, and other intellectual property rights in all countries and territories worldwide and under any
international conventions (“Intellectual Property Rights”). 
 To preclude any possible uncertainty, I have set forth on Exhibit A
attached hereto a complete list of Developments that I have, alone or jointly with others, conceived, developed or reduced to practice prior to the commencement of my employment with the Company that I consider to be my property or the property of
third parties and that I wish to have excluded from the scope of this Agreement (“Prior Inventions”). I have also listed on Exhibit A all patents and patent applications in which I am named as an inventor, other than those which
have been assigned to the Company or any of its Affiliates (“Other Patent Rights”). If no such disclosure is attached, I represent that there are no Prior Inventions or Other Patent Rights. If, in the course of my employment with the
Company, I incorporate a Prior Invention into a Company product, process or machine or other work done for the Company (including for any of its Affiliates), I hereby grant to the Company a nonexclusive, royalty-free, irrevocable, worldwide license
(with the full right to sublicense) to make, have made, modify, use and sell such Prior Invention. Notwithstanding the foregoing, I will not incorporate, or permit to be incorporated, Prior Inventions in any Company-Related Development without the
Company’s prior written consent. 

 

  
 2 

 This Agreement does not obligate me to assign to the Company any Development which, in the judgment of the
Company, reasonably exercised, is developed entirely on my own time and does not relate to the business efforts or research and development efforts in which, during the period of my employment, the Company or any of its Affiliates actually is
engaged or reasonably would be engaged, and does not result from the use of premises or equipment owned or leased by the Company or any of its Affiliates. However, I will also promptly disclose to the Company any such Developments for the purpose of
determining whether they qualify for such exclusion. I understand that to the extent this Agreement is required to be construed in accordance with the laws of any state that precludes a requirement in an employee agreement to assign certain classes
of inventions made by an employee, this paragraph 5 will be interpreted not to apply to any invention that a court rules and/or the Company agrees falls within such classes. I also hereby waive all claims to any moral rights or other special rights
which I may have or accrue in any Company-Related Developments. 
 7.    Documents and Other Materials. I will keep and
maintain adequate and current records of all Proprietary Information and Company-Related Developments developed by me during my employment, which records will be available to and remain the sole property of the Company at all times. 

All files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets,
program listings, blueprints, models, prototypes, or

 
other written, photographic or other tangible material containing Proprietary Information, whether created by me or others, which come into my custody or possession, are the exclusive property of
the Company to be used by me only in the performance of my duties for the Company. Any property situated on the Company’s premises and owned by the Company, including without limitation computers, disks and other storage media, filing cabinets
or other work areas, is subject to inspection by the Company or any of its Affiliates at any time with or without notice. In the event of the termination of my employment for any reason, I will deliver to the Company all files, letters, notes,
memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, program listings, blueprints, models, prototypes, or other written, photographic or other tangible material containing
Proprietary Information, and other materials of any nature pertaining to the Proprietary Information of the Company or any of its Affiliates and to my work, and will not take or keep in my possession any of the foregoing or any copies. 

8.    Enforcement of Intellectual Property Rights. I will cooperate fully with the Company, both during and after my
employment with the Company, with respect to the procurement, maintenance and enforcement of Intellectual Property Rights in Company-Related Developments. I will sign all papers, including without limitation copyright applications, patent
applications, declarations, oaths, assignments of priority rights, and powers of attorney, which the Company or any of its Affiliates may deem necessary or desirable in order to protect its or their rights and interests in any Company -Related
Development. If the Company or any of its Affiliates is unable, after reasonable effort, to secure my signature on any such papers, I hereby irrevocably

 

  
 3 

 
designate and appoint each officer of the Company as my agent and attorney-in-fact to execute any such papers on my
behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its or any of its Affiliates’ rights and interests in any Company-Related Development. 

9.    Non-Competition and Non-Solicitation.
In order to protect the Company’s Proprietary Information and good will, during my employment and for a period of twelve (12) months following the termination of my employment for any reason (the “Restricted Period”), I will not
directly or indirectly, whether as owner, partner, shareholder, director, manager, consultant, agent, employee, co-venturer or otherwise, engage, participate or invest in any business activity anywhere in the
United States that (i) as its primary purpose, develops, manufactures or markets products that are known to modulate a Current or Prospective Target as their principle mode of action, or (ii) as its primary purpose, is prosecuting any
R&D programs, that are directly competitive with or highly similar to a Current or Prospective Target program of the Company or any of its Affiliates; provided that this shall not prohibit any possible investment in publicly traded stock of a
company representing less than one percent of the stock of such company. A “Current or Prospective Target” refers to any target that the Company or any of its Affiliates is actively prosecuting, or any target that is under consideration by
the Company or any of its Affiliates as of the end date of my employment. In addition, during the Restricted Period, I will not, directly or indirectly, in any manner, other than for the benefit of the Company, (a) call upon, solicit, divert or
take away any of the customers, business or prospective customers of the Company or any of its Affiliates or any of its or their suppliers,

 
and/or (b) solicit, entice or attempt to persuade any other employee or consultant of the Company or any of its Affiliates to leave the services of the Company or such Affiliates for any
reason. I acknowledge and agree that if I violate any of the provisions of this paragraph 8, the running of the Restricted Period will be extended by the time during which I engage in such violation(s). 

10.    Government Contracts. I acknowledge that the Company may have from time to time agreements with other persons or with
the United States Government or its agencies that impose obligations or restrictions on the Company or any of its Affiliates regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work.
I agree to comply with any such obligations or restrictions upon the direction of the Company. In addition to the rights assigned under paragraph 5, I also assign to the Company (or any of its nominees) all rights which I have or acquired in any
Developments, full title to which is required to be in the United States under any contract between the Company or any of its Affiliates and the United States or any of its agencies. 

11.    Prior Agreements. I hereby represent that I am not bound by the terms of any agreement with any previous employer or
other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of my employment with the Company or to refrain from competing, directly or indirectly, with the business of such previous
employer or any other party. I further represent that my performance of all the terms of this Agreement as an employee of the Company does not and will not breach any agreement to keep in confidence proprietary information,

 

  
 4 

 
knowledge or data acquired by me in confidence or in trust prior to my employment with the Company. I will not disclose to the Company or any of its Affiliates or induce the Company or any of its
Affiliates to use any confidential or proprietary information or material belonging to any previous employer or others. 

12.    Remedies Upon Breach. I understand that the restrictions contained in this Agreement are necessary for the protection
of the business and goodwill of the Company and any of its Affiliates and I consider them to be reasonable for such purpose. Any breach of this Agreement is likely to cause the Company or any of its Affiliates substantial and irrevocable damage and
therefore, in the event of such breach, the Company, in addition to such other remedies which may be available, will be entitled to specific performance and other injunctive relief. Further, I understand that in the event that any action or
proceeding is initiated to enforce or interpret the provisions of this Agreement, or to recover for a violation of this Agreement, the prevailing party in any such action or proceeding shall be entitled to its costs and reasonable attorneys’
fees. 
 13.    Publications and Public Statements. I will obtain the Company’s written approval before publishing or
submitting for publication any material that relates to my work at the Company and/or incorporates any Proprietary Information. To ensure that the Company delivers a consistent message about its products, services and operations to the public, and
further in recognition that even positive statements may have a detrimental effect on the Company or any of its Affiliates, any statement about the Company or any of its Affiliates that I create, publish or post (or a member of my family, upon my
request or

 
with my knowledge, creates, publishes or posts) during my period of employment and for twelve (12) months thereafter, on any media accessible by the public, including but not limited to
electronic bulletin boards and Internet-based chat rooms, must first be reviewed and approved by an officer of the Company before it is released in the public domain. 

14.    Survival and Assignment by the Company and At-Will Employment. I understand
that my obligations under this Agreement will continue in accordance with its express terms regardless of any changes in my title, position, duties, salary, compensation or benefits or other terms and conditions of employment. I acknowledge and
agree that my employment with the Company is at-will, meaning that either I or the Company may terminate the employment relationship at any time for any reason, with or without cause or notice. I further
understand that my obligations under this Agreement will continue following the termination of my employment regardless of the manner of such termination and will be binding upon my heirs, executors and administrators. The Company will have the
right to assign this Agreement to its affiliates, successors and assigns. I expressly consent to be bound by the provisions of this Agreement for the benefit of the Company or any parent, subsidiary or affiliate to whose employ I may be transferred
without the necessity that this Agreement be re-executed at the time of such transfer. 
 15.    Disclosure to Future
Employers. In the event that I am no longer an employee of the Company, I consent to notification by the Company to my new employer or its agents regarding my rights and obligations under this Agreement.

 

  
 5 

 16.    Severability. In case any provisions (or portions thereof) contained in
this Agreement shall, for any reason, be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such
invalid, illegal or unenforceable provision had never been contained herein. If, moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope,
activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear. 

17.    Entire Agreement and Modification. This Agreement supersedes all prior agreements, whether written or oral, with
respect to the subject matter hereof. No amendment, modification or waiver of any of my obligations under this Agreement shall be valid unless made in writing and signed by both me and the Company. 

18.    Interpretation. This Agreement will be deemed to be made and entered into in the Commonwealth of Massachusetts, and
will in all respects be interpreted, enforced and governed under the laws of the Commonwealth of Massachusetts. I hereby agree to consent to personal jurisdiction of the state and federal courts situated within Middlesex County, Massachusetts for
purposes of enforcing this Agreement, and waive any objection that I might have to personal jurisdiction or venue in those courts.

 
 

  
 6 

 I UNDERSTAND THAT THIS AGREEMENT AFFECTS IMPORTANT RIGHTS. BY SIGNING BELOW, I CERTIFY THAT I
HAVE READ IT CAREFULLY AND AM SATISFIED THAT I UNDERSTAND IT COMPLETELY. 
 IN WITNESS WHEREOF, the undersigned has executed this
agreement as a sealed instrument as of the date set forth below. 
  

			
	Signed:	 	 /s/ Ronald Renaud

		 	Ronald Renaud

 Date: October 31, 2014 

  
 7 

 EXHIBIT A 

To:        Dan Lynch 

From:    Ron Renaud 

Date:     October 31, 2014 

SUBJECT:    Prior Inventions 

The following is a complete list of all inventions or improvements relevant to the subject matter of my employment by the Company that have
been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by the Company: 
  

					
	☒	  	No inventions or improvements	  	
			
	☐	  	See below:	  	
			
		  	  
	  	
			
		  	  
	  	
			
		  	  
	  	
			
	☐	  	Additional sheets attached	  	
		
	The following is a list of all patents and patent applications in which I have been named as an inventor	  	
			
	☐	  	None	  	
			
	☐	  	See below:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]